Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone

Cancer and Metastasis Reviews

Volumn 26, Issue 3-4, 2007, Pages 685-689

  Sone, Saburo ^a   Yano, Seiji ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Bone metastasis; Lung cancer; Molecular target therapy; Osteoclasts

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; MINODRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; REVEROMYCIN A; UNCLASSIFIED DRUG; VANDETANIB; ZOLEDRONIC ACID;

ANGIOGENESIS; BONE METASTASIS; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MOLECULAR MECHANICS; NATURAL KILLER CELL; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCID MOUSE;

APOPTOSIS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; LUNG NEOPLASMS; OSTEOCLASTS; PYRANS; SPIRO COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 36148999424     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9081-z     Document Type: Review

References (28)

1. Quint, L. E., Francis, I. R., Wahl, R. L., Gross, B. H. (1996). Imaging of lung cancer. In H. I. Pass, J. B. Mitchell, D. H. Johnson, A. T. Turrisi (Eds.), Lung cancer: Principles and practice (pp. 437-470), Philadelphia: Lippincott-Raven.
2. Sullivan, F. J. (1996). Palliative radiotherapy for lung cancer. In H. I. Pass, J. B. Mitchell, D. H. Johnson, A. T. Turrisi (Eds.), Lung cancer: Principles and practice (pp. 775-789). Philadelphia: Lippincott-Raven.
3. Guise, T. A. (2000). Molecular mechanisms of osteolytic bone metastases. Cancer (Phila.), 88, 2892-2898.
4. Hauschka, P. V., Mavrakos, A. E., Iafrati, M. D., Doleman, S. E., Klagsbrun, M. (1986). Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. Journal of Biological Chemistry, 261, 12665-12674.
5. Arguello, F., Baggs, R. B., Frantz, C. N. (1990). Nude rat model for studying metastasis of human tumor cells to bone and bone marrow. Journal of the National Cancer Institute, 82, 408-412.
6. Arguello, F., Baggs, R. B., Frantz, C. N. (1988). A murine model of experimental metastasis to bone and bone marrow. Cancer Research, 48, 6876-6881.
7. Sasaki, A., Boyce, B. F., Story, B., Wright, K. R., Chapman, M., Boyce, R., et al. (1995). Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research, 55, 3551-3557.
8. Iwasaki, T., Higashiyama, M., Kuriyama, K., Sasaki, A., Mukai, M., Shinkai, K., et al. (1997). NG-nitro-l-arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model. Japanese Journal of Cancer Research, 88, 861-866.
9. Rabbani, S. A., Harakidas, P., Bowlin, T., Attardo, G. (1998). Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Research, 58, 3461-3465.
10. Iguchi, H., Onuma, E., Sato, K., Sato, K., Ogata, E. (2001). Involvement of parathyroid hormone-related protein in experimental cachexia induced by a human lung cancer-derived cell line established from a bone metastasis specimen. International Journal of Cancer, 94, 24-27.
11. Yano, S., Nishioka, Y., Izumi, K., Tsuruo, T., Tanaka, T., Miyasaka, M., et al. (1996). Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. International Journal of Cancer, 67, 211-217.
12. Miki, T., Yano, S., Hanibuchi, M., Sone, S. (2000). Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncology Research, 12, 209-217.
13. Lipton, A. (2006). Future treatment of bone metastases. Clinical Cancer Research, 12(20 Pt 2), 6305s-6308s.
14. Siclari, V. A., Guise, T. A., Chirgwin, J. M. (2006). Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer and Metastasis Reviews, 25, 621-633.
15. Guise, T. A., Mundy, G. R. (1998). Cancer and bone. Endocrine Reviews, 19, 18-54.
16. Roodman, G. D. (2001). Biology of osteoclast activation in cancer. Journal of Clinical Oncology, 19, 3562-3571.
17. Ratcliffe, W. A., Hutchesson, A. C., Bundred, N. J., Ratcliffe, J. G. (1992). Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet, 339, 164-167.
18. Miki, T., Yano, S., Hanibuchi, M., Kanematsu, T., Muguruma, H., Sone, S. (2004). Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice. International Journal of Cancer, 108, 511-515.
19. Flanagan, A. M., Chambers, T. J. (1991). Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcified Tissue International, 49, 407-415.
20. Yano, S., Zhang, H., Hanibuchi, M., Miki, T., Goto, H., Uehara, H., et al. (2003). Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clinical Cancer Research, 9, 5380-5385.
21. Ibrahim, A., Scher, N., Williams, G., Sridhara, R., Li, N., Chen, G., et al. (2003). Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clinical Cancer Research, 9, 2394-2399.
22. Takahashi, H., Yamashita, Y., Takaoka, H., Nakamura, J., Yoshihama, M., Osada, H. (1997). Inhibitory action of reveromycin A on TGF-alpha-dependent growth of ovarian carcinoma BG-1 in vitro and in vivo. Oncology Research, 9, 7-11.
23. Miyamoto, Y., Machida, K., Mizunuma, M., Emoto, Y., Sato, N., Miyahara, K., et al. (2002). Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G1-specific inhibitor Reveromycin A. Journal of Biological Chemistry, 277, 28810-28814.
24. Woo, J. T., Kawatani, M., Kato, M., Shinki, T., Yonezawa, T., Kanoh, N., et al. (2006). Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proceedings of the National Academy of Sciences of the United States of America, 103, 4729-4734.
25. Muguruma, H., Yano, S., Kakiuchi, S., Uehara, H., Kawatani, K., Osada, H., et al. (2005). Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an anti-osteoclastic activity. Clinical Cancer Research, 11, 8822-8828.
26. Ferrara, N., Gerber, H. P., LeCouter, J. (2003). The biology of VEGF and its receptors. Nature Medicine, 9, 669-676.
27. Yano, S., Muguruma, H., Matsumori, Y., Goto, H., Nakataki, E., Edakuni, N., et al. (2005). Antitumor vascular strategy for controlling experimental metastatic spread of human small cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficiency mice. Clinical Cancer Research, 11, 8789-8798.
28. Herbst, R. S. (2006). Therapeutic options to target angiogenesis in human malignancies. Expert Opinion on Emerging Drugs, 11, 635-650.